Black Diamond Therapeutics (BDTX) Preferred Stock Liabilities (2018 - 2019)
Black Diamond Therapeutics (BDTX) posted Preferred Stock Liabilities of $200.6 million for Q4 2019, up 73.15% on a QoQ basis from $115.8 million in Q3 2019, and up 230.05% year-over-year from $60.8 million in Q4 2018.
Black Diamond Therapeutics (BDTX) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
Black Diamond Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $200.6 million for Q4 2019.
- Quarterly Preferred Stock Liabilities rose 230.05% year-over-year to $200.6 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $200.6 million (up 230.05% YoY) and the FY2019 annual result came in at $200.6 million, up 230.05% from the prior year.
- Preferred Stock Liabilities was $200.6 million for Q4 2019 at Black Diamond Therapeutics, up from $115.8 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $200.6 million in Q4 2019 and bottomed at $60.8 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Black Diamond Therapeutics | 99.59 Mn | -18.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 200.57 Mn |
| Sep 30, 2019 | 115.84 Mn |
| Jun 30, 2019 | 60.77 Mn |
| Mar 31, 2019 | 60.77 Mn |
| Dec 31, 2018 | 60.77 Mn |